TP53 and neoplasm: We previously demonstrated that TP53 co-driver mutations are associated with a worse tumour response to radiotherapy and a poorer outcome [41] suggesting that additional molecular alterations can deeply modify the phenotype induced by the driver histone H3 mutation.